Jubilant, BioLeap announce drug discovery pact

Bangalore-based Jubilant Biosys Ltd announced a drug discovery partnership with BioLeap, LLC, USA, leader in computational fragment-based drug design.

Bangalore-based Jubilant Biosys Ltd, a subsidiary of integrated pharmaceuticals player Jubilant Organosys Ltd, announced on Tuesday a drug discovery partnership with BioLeap, LLC, USA, leader in computational fragment-based drug design.

HT Image

Under this partnership BioLeap and Jubilant will integrate BioLeap’s computational fragment based drug design platform with Jubilant’s expertise in chemistry, biology and crystallography to offer a highly competitive preclinical drug development platform.

Commenting on this, Sri Mosur, CEO and President, Jubilant Biosys, said, "we are very pleased to partner with BioLeap to offer the pharmaceutical industry our combined ‘best in class’ pre-clinical drug discovery capabilities.”

The partnership will provide customers with integrated pre-clinical drug discovery services from lead identification and optimization to investigational new drug candidate selection, for multiple therapeutic areas.

“This partnership leverages and combines the innovation capabilities of Jubilant Biosys in pharmaceutical discovery and pre-clinical development with BioLeap’s leading edge computational fragment-based design capabilities, to deliver high quality, cost-effective pre-clinical drug discovery services”, said Gerald Evans, Chief Business Officer, BioLeap.